Free Newsletter
SPOTLIGHT: New data on Actemra
Roche's RA drug Actemra showed equal efficacy rates when compared with other anti-TNF therapies in a late-stage trial, according to researchers. About 58 percent of the patients taking the drug had a 20 percent improvement in their condition, a significant drop from the 74 percent of patients who marked similar progress in a mid-stage trial. Report
Comments
By Anonymous | Posted 12:02pm | May 9, 2008
Does anyone know when Actemra will be FDA approved and available to patients outside those in the clinical trials?






Click here to get the FierceBiotech email newsletter for FREE!
Be the first to comment